Traci L Bricker
Overview
Explore the profile of Traci L Bricker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
1630
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jiang H, Joshi A, Gan T, Janowski A, Fujii C, Bricker T, et al.
bioRxiv
. 2023 Mar;
PMID: 36993345
Importance: RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contain functional structures to support virus replication, translation and evasion of the host antiviral immune response. The 3' untranslated...
12.
Frumkin L, Lucas M, Scribner C, Ortega-Heinly N, Rogers J, Yin G, et al.
Front Immunol
. 2022 Jun;
13:899617.
PMID: 35720389
Clinical Trial Registration: https://www.clinicaltrials.gov/ct2/show/NCT04567810, identifier NCT04567810.
13.
Darling T, Ying B, Whitener B, VanBlargan L, Bricker T, Liang C, et al.
Med
. 2022 May;
3(5):309-324.e6.
PMID: 35584653
Background: Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019, viral variants with greater transmissibility or immune-evasion properties have arisen, which could jeopardize recently deployed vaccine-...
14.
Janowski A, Jiang H, Fujii C, Owen M, Bricker T, Darling T, et al.
bioRxiv
. 2022 May;
PMID: 35547847
The stem-loop II motif (s2m) is an RNA element present in viruses from divergent viral families, including astroviruses and coronaviruses, but its functional significance is unknown. We created deletions or...
15.
DeGrace M, Ghedin E, Frieman M, Krammer F, Grifoni A, Alisoltani A, et al.
Nature
. 2022 Apr;
605(7911):640-652.
PMID: 35361968
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or vaccination. To address the public health threat caused...
16.
Son J, Huang S, Zeng Q, Bricker T, Case J, Zhou J, et al.
mBio
. 2022 Jan;
13(1):e0337721.
PMID: 35038906
Pathogenic coronaviruses are a major threat to global public health. Here, using a recombinant reporter virus-based compound screening approach, we identified small-molecule inhibitors that potently block the replication of severe...
17.
Su W, Sia S, Schmitz A, Bricker T, Starr T, Greaney A, et al.
mBio
. 2021 Sep;
12(5):e0239521.
PMID: 34517754
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein is the main target for neutralizing antibodies. These antibodies can be elicited through immunization or passively transferred as therapeutics in...
18.
VanBlargan L, Adams L, Liu Z, Chen R, Gilchuk P, Raju S, et al.
Immunity
. 2021 Sep;
54(10):2399-2416.e6.
PMID: 34481543
With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with increased transmissibility and potential resistance, antibodies and vaccines with broadly inhibitory activity are needed. Here, we developed...
19.
Schmitz A, Turner J, Liu Z, Zhou J, Aziati I, Chen R, et al.
Immunity
. 2021 Aug;
54(9):2159-2166.e6.
PMID: 34464596
The emergence of SARS-CoV-2 antigenic variants with increased transmissibility is a public health threat. Some variants show substantial resistance to neutralization by SARS-CoV-2 infection- or vaccination-induced antibodies. Here, we analyzed...
20.
Bricker T, Darling T, Hassan A, Harastani H, Soung A, Jiang X, et al.
Cell Rep
. 2021 Jul;
36(3):109400.
PMID: 34245672
The development of an effective vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiologic agent of coronavirus disease 2019 (COVID-19), is a global priority. Here, we compare the...